Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member
SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member.
Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companies like Vineti, Sotio, and Dendreon, Hagen intimately understands how pharma and biotech companies operate and scale from startup to global organization. Her experiences as a founder, C-Suite executive, and key operator in the growth and exits of numerous companies provide A-Alpha Bio with a wealth of valuable insights and lessons learned.
"We are thrilled to welcome Heidi to our Board of Directors," said David Younger, CEO and Co-Founder of A-Alpha Bio. "Her extensive experience as a biotechnology leader, founder, and operator will be instrumental in successfully developing our platforms, progressing our pipeline, and advancing A-Alpha Bio's mission to improve human health by measuring and engineering protein-protein interactions."
Hagen has remained at the forefront of biotech innovation and business leadership with expertise spanning technical areas from protein therapeutics to cell therapies. Based in Seattle, Hagen will be on the ground to support and share her expertise and network with the A-Alpha Bio team.
"I am excited to join A-Alpha Bio's Board of Directors and collaborate with this dynamic team of biologists, protein engineers, and data scientists," said Hagen. "I believe that the convergence of machine learning and synthetic biology holds immense potential for advancing the development of novel therapeutics, particularly in the area of protein-protein interactions. Drawing from my diverse experiences in biotechnology, I am eager to work alongside A-Alpha Bio to achieve their goals and significantly impact human health."
Hagen most recently served as Chief Technology Officer at Sonoma Biotherapeutics, an immune tolerance company engineering regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases. Prior to that, she focused on precision medicine through her roles as the Co-Founder and former Chief Strategy Officer at Vineti, the Global Chief Operating Officer at Sotio, the Senior Vice President of Operations at Dendreon Corporation, and the Senior Manager of Supply Operations at Immunex Inc. In addition, Hagen serves as a board member and Governance Committee Chair for Obsidian Therapeutics and Vericel Corporation (NASDAQ:VCEL). Previously, Hagen also served on the boards of Alaunos Therapeutics and Lykan Biosciences.
Hagen earned her B.S. in cell and molecular biology, her M.S. in bioengineering, and her M.B.A all from the University of Washington, where her studies focused on the interaction between science and business.
For more information on A-Alpha Bio, please visit: https://www.aalphabio.com/.
About A-Alpha Bio
A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.
The company's AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously. Protein binding data is incorporated into the company's AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.
A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/.
Media Contact
Juan Avila, A-Alpha Bio, 5125894486, juan@jones-dilworth.com
SOURCE A-Alpha Bio
Share this article